Stock AnalizMiniMed Group, Inc. MMED
Medical/Dental Instruments · IPO 2026 · data as of November 13, 2026
MiniMed Group, Inc. (MMED) is a healthcare company listed in the US with a market value of about $5.1B. In the twelve months to July 31, 2026 it had revenue of $3.2B and net income of -$314M, a net margin of -9.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 67% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2026 | 2025 | 2024 |
|---|---|---|---|---|
| Revenue | $3.2B | $3.1B | $2.7B | $2.5B |
| Net income | -$314M | -$333M | -$213M | -$112M |
| Free cash flow | -$316M | -$420M | -$53M | -$107M |
| EPS (diluted) | $-1.12 | $-1.30 | $-0.84 | $-0.44 |
| Net margin | -9.7% | -10.7% | -7.8% | -4.5% |
| ROIC | — | -4.1% | -3.4% | -1.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $25.47, 42% above the current price; targets range from $15.00 to $30.00; the consensus rating is “Buy”; expected EPS is $0.70 for the fiscal year ending April 30, 2027.
Frequently asked questions
Is MiniMed Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 67% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does MiniMed Group pay a dividend?
Not currently.
Is MiniMed Group a good stock to buy?
We do not give buy or sell advice. MiniMed Group scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.